Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegfilgrastim with R-ACVBP in High-Risk DLBCL
NCT00169143Phase 2Completed
- Sponsor
- Lymphoma Study Association
- Start
- May 2004
- Primary completion
- Jan 2007
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegfilgrastim in neutropenia, sponsored by Lymphoma Study Association. Primary endpoint: Optimal combined dose intensity of the drug regimen. Started May 2004; status: completed.
02
Drugs
pegfilgrastim
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT00169143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00169143.